FGFR3 and breast cancer: The data presented here suggest that surveillance by mutation analysis for FGFR3, PIK3CA and the RAS genes in combination with extension of the period between cystoscopies could be a useful follow-up strategy for those patients presenting with a mutant NMI-BC, grade 1–2 primary tumor.